Evaluation of a new 99mTc-Bombesin analog in differentiation of malignant from benign breast tumors

Document Type: Original Article

Authors

1 Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran

2 Department of Surgery, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

3 Nuclear Science and Technology Research Institute, Atomic Energy Organization of Iran (AEOI), Tehran, Iran

4 Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Introduction: The gastrin releasing peptide (GRP) receptor is over expressed in a variety of common human tumors. Radiolabeled bombesin analogues have exhibited high binding affinity for these receptors. The aim of this study was to assess the value of a new 99mTc-bombesin analog in the differentiation of malignant from benign breast tumors. Methods: 99mTc-bombesin scans were performed in 21 patients (45±21years) with breast tumor. Post-injection of 555-740 MBq 99mTc-bombesin, the dynamic imaging of the chest with 60 seconds for each frame up to 20 minutes was acquired. Subsequently, 360◦ image SPECTs of the chest was performed in 120 steps, 20 seconds per projection. In addition, whole-body anterior and posterior views were obtained 60 and 180 min after injection. Definite diagnosis was based on excisional biopsy and histopathological examination. Results: Thirteen patients demonstrated breast carcinoma and 8 patients were diagnosed as benign lesions. 11 out of 13 patients with breast carcinoma showed radiotracer uptake in the breast lesion. Nine out of 13 patients with breast carcinoma showed axillary lymph node involvement from which only two revealed radiotracer accumulation in the axillary lesion. All patients with benign lesions revealed negative scan. Delayed planar whole body images showed no additional diagnostic information in comparison to one-hour images. The sensitivity, specificity, PPV and NPV of 99mTc-bombesin scan were 84.6%, 100%, 100% and 80%, respectively. Conclusion: Our data suggest that this new 99mTc-bombesin analog could be useful in SPECT imaging of primary breast cancer.

Keywords

Main Subjects


Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 2004;6(6):229-39.

Liu Z, Yan Y, Liu S, Wang F, Chen X. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconjug Chem. 2009 May 20;20(5):1016-25.

Parry JJ, Andrews R, Rogers BE. MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor. Breast Cancer Res Treat. 2007 Jan;101(2):175-83.

Lewin JM, D'Orsi CJ, Hendrick RE, Moss LJ, Isaacs PK, Karellas A, Cutter GR. Clinical comparison of full-field digital mammography and screen-film mammography for detection of breast cancer. AJR Am J Roentgenol. 2002 Sep;179(3):671-7.

Smith RA, Saslow D, Sawyer KA, Burke W, Costanza ME, Evans WP 3rd, Foster RS Jr, Hendrick E, Eyre HJ, Sener S; American Cancer Society High-Risk Work Group; American Cancer Society Screening Older Women Work Group; American Cancer Society Mammography Work Group; American Cancer Society Physical Examination Work Group; American Cancer Society New Technologies Work Group; American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin. 2003 May-Jun;53(3):141-69.

Buchberger W, DeKoekkoek-Doll P, Springer P, Obrist P, Dünser M. Incidental findings on sonography of the breast: clinical significance and diagnostic workup. AJR Am J Roentgenol. 1999 Oct;173(4):921-7.

Davis PL, McCarty KS Jr. Sensitivity of enhanced MRI for the detection of breast cancer: new, multicentric, residual, and recurrent. EurRadiol. 1997;7Suppl 5:289-98.

Freer TW, Ulissey MJ. Screening mammography with computer-aided detection: prospective study of 12,860 patients in a community breast center. Radiology. 2001 Sep;220(3):781-6.

Kolb TM, Lichy J, Newhouse JH. Occult cancer in women with dense breasts: detection with screening US--diagnostic yield and tumor characteristics. Radiology. 1998 Apr;207(1):191-9.

Scopinaro F, Varvarigou AD, Ussof W, De Vincentis G, Sourlingas TG, Evangelatos GP, Datsteris J, Archimandritis SC. Technetium labeled bombesin-like peptide: preliminary report on breast cancer uptake in patients. Cancer BiotherRadiopharm. 2002 Jun;17(3):327-35.

Van de Wiele C, Dumont F, VandenBroecke R, Oosterlinck W, Cocquyt V, Serreyn R, Peers S, Thornback J, Slegers G, Dierckx RA. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med. 2000 Nov;27(11):1694-9.

Retzloff LB, Heinzke L, Figureoa SD, Sublett SV, Ma L, Sieckman GL, Rold TL, Santos I, Hoffman TJ, Smith CJ. Evaluation of [99mTc-(CO)3-X-Y-Bombesin(7-14)NH2] conjugates for targeting gastrin-releasing peptide receptors overexpressed on breast carcinoma. Anticancer Res. 2010 Jan;30(1):19-30.

Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999 Mar 1;59(5):1152-9.

Halmos G, Wittliff JL, Schally AV. Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res. 1995 Jan 15;55(2):280-7.

Gugger M, Reubi JC. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol. 1999 Dec;155(6):2067-76.

Reubi C, Gugger M, Waser B. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptortumour targeting. Eur J Nucl Med Mol Imaging. 2002 Jul;29(7):855-62.

Smith CJ, Volkert WA, Hoffman TJ. Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. Nucl Med Biol. 2003 Nov;30(8):861-8.

Shirmardi SP, Gandomkar M, Mazidi M, Shafiei M, GhannadiMaragheh M. Synthesis and evaluation of a new bombesin analog labeled with 99mTc as a GRP receptor imaging agent. J RadioanalNucl Chem. 2011;288:327-335.

Varvarigou AD, Scopinaro F, Leondiadis L, Corleto V, Schillaci O, De Vincentis G, Sourlingas TG, Sekeri-Pataryas KE, Evangelatos GP, Leonti A, Xanthopoulos S, DelleFave G, Archimandritis SC. Synthesis, chemical, radiochemical and radiobiological evaluation of a new 99mTc-labelled bombesin-like peptide. Cancer BiotherRadiopharm. 2002 Jun;17(3):317-26.

Scopinaro F, Di Santo GP, Tofani A, Massari R, Trotta C, Ragone M, Archimandritis S, Varvarigou AD. Fast cancer uptake of 99mTc-labelled bombesin (99mTc BN1). In Vivo. 2005 Nov-Dec;19(6):1071-6.

Scopinaro F, Varvarigou A, Ussof W, De Vincentis G, Archimandritis S, Evangelatos G, Corleto V, Pulcini A, Capoccetti F, Remediani S, Massa R. Breast cancer takes up 99mTc bombesin. A preliminary report. Tumori. 2002 May-Jun;88(3):S25-8.

Scopinaro F, De Vincentis G, Varvarigou AD, Laurenti C, Iori F, Remediani S, Chiarini S, Stella S. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1378-82.

Shariati F, Aryana K, Fattahi A, Forghani MN, Azarian A, Zakavi SR, Sadeghi R, Ayati N, Sadri K.Diagnostic value of 99mTc-bombesin scintigraphy for differentiation of malignant from benign breast lesions.Nucl Med Commun. 2014 Jun;35(6):620-5.

Van de Wiele C, Phonteyne P, Pauwels P, Goethals I, Van den Broecke R, Cocquyt V, Dierckx RA. Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry. J Nucl Med. 2008 Feb;49(2):260-4.